Protocol
12-279
Full Title
A Dose-Finding Study of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Purpose
Some lung cancers are caused by a change, or mutation, in a gene called EGFR. Afatinib is an investigational drug shown to be active against cancers with this mutation. It is not, however, routinely used in combination with radiation therapy.
The use of chemotherapy and radiation therapy given together at the same time is an approach to treating lung cancers that cannot be surgically removed. In this study, researchers want to find the best dose of afatinib that can be given with chemotherapy and radiation therapy in patients with EGFR-mutant non-small cell lung cancers. The chemotherapy drugs used in this study will include cisplatin or carboplatin in addition to pemetrexed.
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have inoperable stage III non-small cell lung cancer that contains a mutation in EGFR.
- Patients may not have received prior chemotherapy or radiation therapy for this lung cancer, nor prior treatment with a drug that targets EGFR.
- Patients must be candidates for chemotherapy that includes cisplatin or carboplatin and pemetrexed.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Jamie Chaft at 646-888-4545.
Disease(s)
Lung Cancer, Non-Small Cell
Locations
ClinicalTrials.gov
Related Diseases
